David Rooklin, PhD

David Rooklin earned a Ph.D. in computational biology from NYU in 2012 and has over 15 years experience in molecular dynamics research and application. He is the inventor of AlphaSpace, a computational approach to identify druggability in challenging targets. He has published multiple peer-reviewed papers (including cover articles) on the use of the platform to discover druggable sites at protein-protein interactions (PPIs). During his time at NYU, he was awarded two grants for NIH Research Projects with funding over $1M. In 2016, David won the Stern Business School’s $200K Entrepreneurs Challenge – Tech Division. In 2017, he won NYU’s Technology Advancement and Commercialization Award and cofounded Redesign Science to commercialize the application of molecular dynamics + AI for new target drug discovery. To date, Redesign has raised $17M in seed funding and is rapidly advancing a pipeline of early stage small molecules for oncology and inflammatory diseases.